Damora Therapeutics, Inc. - Asset Resilience Ratio
Damora Therapeutics, Inc. (DMRA) has an Asset Resilience Ratio of 0.00% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2024)
This chart shows how Damora Therapeutics, Inc.'s Asset Resilience Ratio has changed over time. Check Damora Therapeutics, Inc. strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Damora Therapeutics, Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see DMRA market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Damora Therapeutics, Inc. maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Damora Therapeutics, Inc. Industry Peers by Asset Resilience Ratio
Compare Damora Therapeutics, Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Abivax SA
PA:ABVX |
Biotechnology | 2.34% |
|
Genscript Biotech Corporation
F:G51 |
Biotechnology | 13.79% |
|
Zealand Pharma A/S
CO:ZEAL |
Biotechnology | 63.98% |
|
ZAI LAB LTD0000006
F:1ZLB |
Biotechnology | 0.91% |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497 |
Biotechnology | 0.02% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513 |
Biotechnology | 34.30% |
Annual Asset Resilience Ratio for Damora Therapeutics, Inc. (2021–2024)
The table below shows the annual Asset Resilience Ratio data for Damora Therapeutics, Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | $0.00 | $17.13 Million | -- |
| 2023-12-31 | 30.57% | $11.69 Million | $38.23 Million | -6.92pp |
| 2022-12-31 | 37.49% | $27.44 Million | $73.19 Million | +6.70pp |
| 2021-12-31 | 30.79% | $37.63 Million | $122.22 Million | -- |
About Damora Therapeutics, Inc.
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to u… Read more